{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:40:52Z","timestamp":1788921652603,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer SLU"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40487-025-00333-7","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T03:59:48Z","timestamp":1743998388000},"page":"381-395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician\u2019s Choice of Treatment in Spain"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9001-9754","authenticated-orcid":false,"given":"Cristina","family":"Encinas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4752-3218","authenticated-orcid":false,"given":"Patrick","family":"Hlavacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Llinares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8879-3057","authenticated-orcid":false,"given":"Sof\u00eda","family":"Toribio-Castell\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2809-7399","authenticated-orcid":false,"given":"David","family":"Carcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0004-6469","authenticated-orcid":false,"given":"Jordi","family":"As\u00eds-Montalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"333_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med"},{"key":"333_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","volume":"12","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for relapsed and\/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015;12:42\u201354.","journal-title":"Nat Rev Clin Oncol"},{"key":"333_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.soncn.2017.05.012","volume":"33","author":"K Brigle","year":"2017","unstructured":"Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 2017;33:225\u201336.","journal-title":"Semin Oncol Nurs"},{"key":"333_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"333_CR5","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica. Las cifras del c\u00e1ncer en Espa\u00f1a\u20142024. 2024. https:\/\/seom.org\/images\/publicaciones\/informes-seom-de-evaluacion-de-farmacos\/LAS_CIFRAS_2024.pdf. Accessed 30 Oct 2024."},{"key":"333_CR6","unstructured":"GLOBOCAN. Cancer today. 2020. https:\/\/gco.iarc.fr\/today\/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=724&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=0&include_nmsc_other=1. Accessed 10 July 2023."},{"key":"333_CR7","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2217\/fon-2020-0970","volume":"17","author":"G Kanas","year":"2021","unstructured":"Kanas G, Clark O, Keeven K, Nersesyan K, Sansbury L, Hogea C. Estimate of multiple myeloma patients by line of therapy in the USA: population-level projections 2020\u20132025. Future Oncol. 2021;17:921\u201330.","journal-title":"Future Oncol"},{"key":"333_CR8","unstructured":"SEOM (Spanish Society of Medical Oncology). Las cifras del c\u00e1ncer en Espa\u00f1a\u20142023. 2023. https:\/\/seom.org\/images\/Las_cifras_del_Cancer_en_Espana_2023.pdf. Accessed 12 June 2024."},{"key":"333_CR9","doi-asserted-by":"publisher","first-page":"107327482211429","DOI":"10.1177\/10732748221142945","volume":"30","author":"KA Kapinos","year":"2023","unstructured":"Kapinos KA, Hu E, Trivedi J, Geethakumari PR, Kansagra A. Cost-effectiveness analysis of CAR T-cell therapies vs antibody drug conjugates for patients with advanced multiple myeloma. Cancer Control. 2023;30:107327482211429.","journal-title":"Cancer Control"},{"key":"333_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2217\/fon-2020-1003","volume":"17","author":"D Madduri","year":"2021","unstructured":"Madduri D, Hagiwara M, Parikh K, et al. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future Oncol. 2021;17:503\u201315.","journal-title":"Future Oncol"},{"key":"333_CR11","unstructured":"National Cancer Institute. Cancer stat facts: myeloma. SEER. 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed 30 Oct 2024."},{"key":"333_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/13696998.2023.2173466","volume":"26","author":"K Karampampa","year":"2023","unstructured":"Karampampa K, Zhang W, Venkatachalam M, Cotte F-E, Dhanda D. Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed\/refractory multiple myeloma patients in Canada and France. J Med Econ. 2023;26:243\u201353.","journal-title":"J Med Econ"},{"key":"333_CR13","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"M-V Mateos","year":"2022","unstructured":"Mateos M-V, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36:1371\u20136.","journal-title":"Leukemia"},{"key":"333_CR14","unstructured":"Llinares J, Toribio S, Garc\u00eda LF, et al. Treatment patterns of patients with multiple myeloma in Spain. How are triple-class exposed patients being managed? Conference communication. 10th World congress on controversies in multiple myeloma (COMy), 23-26 May 2024, Paris."},{"key":"333_CR15","unstructured":"Grupo Espa\u00f1ol de Mieloma, Pethema. Gu\u00eda de Mieloma M\u00faltiple. 2021. https:\/\/www.fundacionpethema.es\/sites\/default\/files\/2024-04\/Guia-Mieloma-Multiple-21-04-2021.pdf. Accessed 31 July 2024."},{"key":"333_CR16","unstructured":"Aguilar Franco C, B\u00e1rez Garc\u00eda A, Blum Dom\u00ednguez A, et al. Hematogu\u00eda mieloma. 2024. https:\/\/www.sclhh.org\/docs\/pdf\/consenso\/guia%20mieloma%202024_version%20digital.pdf. Accessed 20 Nov 2024."},{"key":"333_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.136","author":"MH Tomasson","year":"2024","unstructured":"Tomasson MH, Iida S, Niesvizky R, et al. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study. Hemasphere. 2024. https:\/\/doi.org\/10.1002\/hem3.136.","journal-title":"Hemasphere"},{"key":"333_CR18","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"333_CR19","doi-asserted-by":"publisher","first-page":"8033","DOI":"10.1200\/JCO.2023.41.16_suppl.8033","volume":"41","author":"NWCJ van de Donk","year":"2023","unstructured":"van de Donk NWCJ, Garfall AL, Benboubker L, et al. Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1. J Clin Oncol. 2023;41:8033.","journal-title":"J Clin Oncol"},{"key":"333_CR20","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1080\/10428194.2024.2313628","volume":"65","author":"I Mol","year":"2024","unstructured":"Mol I, Hu Y, LeBlanc TW, et al. A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed\/refractory multiple myeloma. Leuk Lymphoma. 2024;65:660\u20138.","journal-title":"Leuk Lymphoma"},{"key":"333_CR21","unstructured":"Ministerio de Sanidad, Comit\u00e9 Asesor para la Financiaci\u00f3n de la Prestaci\u00f3n Farmac\u00e9utica del Sistema Nacional de Salud. Gu\u00eda de evaluaci\u00f3n econ\u00f3mica de medicamentos. 2024. https:\/\/www.sanidad.gob.es\/areas\/farmacia\/comitesAdscritos\/prestacionFarmaceutica\/docs\/20240227_CAPF_Guia_EE_definitiva.pdf. Accessed 24 July 2024."},{"key":"333_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/03007995.2023.2277850","volume":"40","author":"I Mol","year":"2024","unstructured":"Mol I, Hu Y, LeBlanc TW, et al. A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician\u2019s choice of treatment in patients with triple-class exposed\/refractory multiple myeloma. Curr Med Res Opin. 2024;40:199\u2013207.","journal-title":"Curr Med Res Opin"},{"key":"333_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"333_CR24","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Karlin L, Benboubker L, et al. Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the MajesTEC-1 study. Conference communication. American Society of Clinical Oncology annual meeting, 2\u20136 June 2023, Chicago.","DOI":"10.1016\/S2152-2650(23)01410-6"},{"key":"333_CR25","doi-asserted-by":"crossref","unstructured":"Sidana S, Moreau P, Garfall AL, et al. Long-term follow-up from MajesTEC-1 of teclistamab,a BCMA\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma. Conference communication. European Hematology Association Congress, 8\u201311 June 2023, Frankfurt.","DOI":"10.1097\/01.HS9.0000970420.62475.d0"},{"key":"333_CR26","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1182\/blood-2023-182130","volume":"142","author":"M Tomasson","year":"2023","unstructured":"Tomasson M, Iida S, Niesvizky R, et al. Long-term efficacy and safety of elranatamab monotherapy in the phase 2 magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM). Blood. 2023;142:3385\u20133385.","journal-title":"Blood"},{"key":"333_CR27","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/bjh.19346","volume":"204","author":"M Mohty","year":"2024","unstructured":"Mohty M, Bahlis NJ, Nooka AK, DiBonaventura M, Ren J, Conte U. Impact of elranatamab on quality of life: patient-reported outcomes from MagnetisMM-3. Br J Haematol. 2024;204:1801\u201310.","journal-title":"Br J Haematol"},{"key":"333_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","volume":"41","author":"M Hern\u00e1ndez Alava","year":"2023","unstructured":"Hern\u00e1ndez Alava M, Pudney S, Wailoo A. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK population study. Pharmacoeconomics. 2023;41:199\u2013207.","journal-title":"Pharmacoeconomics"},{"key":"333_CR29","unstructured":"National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual. 2022. https:\/\/www.nice.org.uk\/process\/pmg36. Accessed 10 July 2023."},{"key":"333_CR30","unstructured":"Gisbert R, Brosa M. Healthcare cost database eSalud. Barcelona. 2018. http:\/\/www.oblikue.com\/bddcostes\/. Accessed 29 Jan 2024."},{"key":"333_CR31","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos. BOTPLUS. 2024. https:\/\/botplusweb.farmaceuticos.com\/. Access 31 Jan 2024."},{"key":"333_CR32","unstructured":"Real Decreto-ley 8\/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico. Bolet\u00edn Oficial del Estado. 2010. https:\/\/www.boe.es\/buscar\/doc.php?id=BOE-A-2010-8228. Accessed 5 June 2023."},{"key":"333_CR33","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"J San Miguel","year":"2013","unstructured":"San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055\u201366.","journal-title":"Lancet Oncol"},{"key":"333_CR34","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621\u201334.","journal-title":"N Engl J Med"},{"key":"333_CR35","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.gaceta.2016.06.005","volume":"31","author":"R Nu\u00f1o-Solin\u00eds","year":"2017","unstructured":"Nu\u00f1o-Solin\u00eds R, Herrera Molina E, Librada Flores S, Orueta Mend\u00eda JF, Cabrera-Le\u00f3n A. Actividad asistencial y costes en los \u00faltimos 3 meses de vida de pacientes fallecidos con c\u00e1ncer en Euskadi. Gac Sanit. 2017;31:524\u201330.","journal-title":"Gac Sanit"},{"key":"333_CR36","unstructured":"Ministerio de Sanidad. BIFIMED: Nomencl\u00e1tor. BIFIMED. 2024. https:\/\/www.sanidad.gob.es\/profesionales\/medicamentos.do. Accessed 30 Oct 2024."},{"key":"333_CR37","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s12325-023-02738-0","volume":"41","author":"P Moreau","year":"2024","unstructured":"Moreau P, Mateos M-V, Gonzalez Garcia ME, et al. Comparative effectiveness of teclistamab versus real-world physician\u2019s choice of therapy in LocoMMotion and MoMMent in triple-class exposed relapsed\/refractory multiple myeloma. Adv Ther. 2024;41:696\u2013715.","journal-title":"Adv Ther"},{"key":"333_CR38","doi-asserted-by":"crossref","unstructured":"Mol I, Hu Y, LeBlanc T, et al. Updated results of a matching-adjusted indirect comparison of elranatamab versus physician\u2019s choice of treatment in patients with triple-class exposed\/refractory multiple myeloma. Conference communication. American Society of Hematology Annual Meeting, 7\u201310 December 2024, San Diego.","DOI":"10.1182\/blood-2024-206856"},{"key":"333_CR39","unstructured":"Mol I, Hu Y, LeBlanc T, et al. Updated results of a matching-adjusted indirect comparison of elranatamab versus teclistamab in patients with triple-class exposed\/refractory multiple myeloma. Conference communication. American Society of Hematology Annual Meeting, 7\u201310 December 2024, San Diego."},{"key":"333_CR40","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S104195","author":"W Chen","year":"2016","unstructured":"Chen W, Yang Y, Chen Y, Du F, Zhan H. Cost-effectiveness of bortezomib for multiple myeloma: a systematic review. ClinicoEcon Outcomes Res. 2016. https:\/\/doi.org\/10.2147\/CEOR.S104195.","journal-title":"ClinicoEcon Outcomes Res"},{"key":"333_CR41","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s40273-019-00828-y","volume":"37","author":"S Fu","year":"2019","unstructured":"Fu S, Wu C-F, Wang M, Lairson DR. Cost effectiveness of transplant, conventional chemotherapy, and novel agents in multiple myeloma: a systematic review. Pharmacoeconomics. 2019;37:1421\u201349.","journal-title":"Pharmacoeconomics"},{"key":"333_CR42","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1080\/14737167.2020.1779064","volume":"21","author":"MM Asrar","year":"2021","unstructured":"Asrar MM, Lad DP, Prinja S, Bansal D. A systematic review of economic evaluations of treatment regimens in multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2021;21:799\u2013809.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"333_CR43","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.3390\/cancers13225606","volume":"13","author":"MR Seefat","year":"2021","unstructured":"Seefat MR, Cucchi DGJ, Dirven S, Groen K, Zweegman S, Blommestein HM. A systematic review of cost-effectiveness analyses of novel agents in the treatment of multiple myeloma. Cancers (Basel). 2021;13:5606.","journal-title":"Cancers (Basel)"},{"key":"333_CR44","unstructured":"Canadian Agency for Drugs and Technologies in Health. Elranatamab (Elrexfio): CADTH Reimbursement Recommendation. 2024]. Elranatamab (Elrexfio): CADTH reimbursement recommendation: indication: for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. Accessed 21 Oct 2024."},{"key":"333_CR45","unstructured":"Phillippo D, Ades T, Dias S, Palmer S, Abrams K, Welton N. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. 2016. https:\/\/research-information.bris.ac.uk\/files\/94868463\/Population_adjustment_TSD_FINAL.com. Accessed 4 Nov 2024."},{"key":"333_CR46","unstructured":"European Medicines Agency. EMA confirms recommendation for non-renewal of authorisation of multiple myeloma medicine Blenrep. 2023. https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-recommendation-non-renewal-authorisation-multiple-myeloma-medicine-blenrep. Accessed 1 Aug 2024."}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00333-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00333-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00333-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:24:40Z","timestamp":1772209480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00333-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00333-7","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cristina Encinas has received honoraria derived from lectures and participation in advisory boards from Amgen, BMS, GSK, Johnson and Johnson, Menarini Stemline, Sanofi and Pfizer. Virginia Lozano, Patrick Hlavacek, Julia Llinares and Sof\u00eda Toribio are employees of Pfizer and may hold Pfizer stock. David Carcedo and Jordi As\u00eds-Montalt are employees of Hygeia Consulting. Joaqu\u00edn Mart\u00ednez-L\u00f3pez has received honoraria derived from research projects from Amgen, Incity, Janssen and Pfizer, and from lectures and participation in advisory boards from Amgen, BMS, Gilead, Incity, Janssen, Novartis, Pfizer and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}